about
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ranCombined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host diseaseAprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells.Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.CD45RB expression defines two interconvertible subsets of human CD4+ T cells with memory function.Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophism.Distinct phenotype of leukemic T cells with various tissue tropismsIntestinal lymphangiectasia, a disease characterized by selective loss of naive CD45RA+ lymphocytes into the gastrointestinal tractPeptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trialImmunomagnetic purification of T cell subpopulations
P50
Q30991546-85E2B507-6C94-4377-A985-187A5F19D65AQ30992721-C367C22C-25B8-41F5-A00F-FCFBA6F2FFA0Q31031408-FFA01D30-8E9F-45CC-8992-DBE82E727BDAQ34572357-CBD52C6C-C5A1-4024-8CB2-920C57190EB4Q35903189-3BE29962-5CDC-425C-B445-C760F80A92B3Q35987293-A5350932-1F42-479E-903A-84A3ED706E86Q41174210-CA06AEFC-2DCB-4DE8-B5E0-8A6026DFC9EFQ44415307-C167F4DB-430C-4F49-8E7B-36977F3E8CEFQ44433152-26DF5938-D1F4-45AF-A32D-2ACD3073C1C4Q44490963-D0B3E16F-5FFD-416F-9FBE-0DBD6CBF375AQ46443858-0570F0FC-63DD-4B06-B120-E867481FFC64Q46653304-C5B7A7DE-62B4-4FC3-9E10-DD503EC1A870Q52058180-4E786C07-3D90-4548-8AF0-C4A57804C61EQ52061715-14CA741E-B9EB-465B-A6CC-DF49C356CC34Q73224677-EBBCDDE3-1886-4D73-8DEE-4A6DD64EEA3EQ77715024-6FF47D67-39E2-46C3-BC12-0F50F94B69E9Q79676511-59DBF090-BC59-4A53-90B5-DFA0F864EC56Q81141987-8E3F74C6-C059-48CD-9945-C9777BFAE37B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kevin J Horgan
@ast
Kevin J Horgan
@en
Kevin J Horgan
@es
Kevin J Horgan
@nl
type
label
Kevin J Horgan
@ast
Kevin J Horgan
@en
Kevin J Horgan
@es
Kevin J Horgan
@nl
prefLabel
Kevin J Horgan
@ast
Kevin J Horgan
@en
Kevin J Horgan
@es
Kevin J Horgan
@nl
P106
P21
P31
P496
0000-0003-0647-9078